MAGEA2: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: MAGEA2

NCBI ID: G4101

MAGEA2

MAGEA2: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The pain can be caused by various conditions, such as cancer, neurological disorders, or injuries, and can be chronic, constant, and severe. Chronic pain can significantly impact a person's quality of life, and in some cases, even their physical health.

The MAGEA family, which includes MAGEA1 and MAGEA2, is a group of genes that encode for proteins involved in the production of pain modulators. MAGEA1 and MAGEA2 have been shown to play important roles in the regulation of pain, and recent studies have identified them as potential drug targets and biomarkers for chronic pain.

MAGEA2: A Potential Drug Target

MAGEA2, or MAGEA family member A2, is a gene that encodes for a protein known as MAGEA2. MAGEA2 is a 21-kDa protein that is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. MAGEA2 has been shown to play a role in the production of endogenous pain modulators, which are naturally occurring compounds that can reduce pain sensitivity.

One of the functions of MAGEA2 is to regulate the production of endogenous pain modulators. MAGEA2 has been shown to interact with various transcription factors, including TrkA, TrkB, andCREB2, to regulate the production of pro-inflammatory cytokines, such as IL-1尾 and TNF-伪, which are involved in pain signaling. MAGEA2 has also been shown to interact with opioid receptors to regulate the production of endogenous opioids, which can act as natural painkillers.

In addition to its role in pain modulation, MAGEA2 has also been shown to play a role in the regulation of inflammation and neuroinflammation. MAGEA2 has been shown to regulate the production of pro-inflammatory cytokines, such as IL-1尾 and TNF-伪, which are involved in the regulation of inflammation. MAGEA2 has also been shown to interact with various signaling pathways, including TGF-β and NF-kappa-B, to regulate the production of pro-inflammatory cytokines.

MAGEA2 as a Potential Biomarker

MAGEA2 has also been shown to be a potential biomarker for chronic pain. Chronic pain can be caused by various conditions, including cancer, neurological disorders, or injuries, and can be chronic, constant, and severe. The production of endogenous pain modulators by MAGEA2 can be affected by various factors, including pain stimuli, making MAGEA2 a potential biomarker for chronic pain.

MAGEA2 has been shown to be involved in the regulation of pain signaling, which is a critical factor in the development and maintenance of chronic pain. MAGEA2 has been shown to regulate the production of pro-inflammatory cytokines, such as IL-1尾 and TNF-伪, which are involved in pain signaling. MAGEA2 has also been shown to interact with opioid receptors to regulate the production of endogenous opioids, which can act as natural painkillers.

In addition to its role in pain signaling, MAGEA2 has also been shown to play a role in the regulation of inflammation and neuroinflammation. MAGEA2 has been shown to regulate the production of pro-inflammatory cytokines, such as IL-1尾 and TNF-伪, which are involved in the regulation of inflammation. MAGEA2 has also been shown to interact with various signaling pathways, including TGF-

Protein Name: MAGE Family Member A2

Functions: Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation

The "MAGEA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets